AI Article Synopsis
- Clinical stage at diagnosis significantly impacts the prognosis and healthcare costs for cutaneous malignant melanoma (CMM) patients, with higher costs at more advanced stages.
- A study in Östergötland, Sweden, revealed that CMM patients incur healthcare costs that are 2.8 times higher than the general population, especially during the first year post-diagnosis.
- Patients diagnosed at clinical stage III-IV, although only 7% of the total, contributed to 27% of the overall healthcare costs, highlighting the financial burden associated with advanced melanoma stages.
Article Abstract
Background: Clinical stage at diagnosis is a strong prognostic factor for death in cutaneous malignant melanoma (CMM), with worse prognosis at higher stages. However, few studies have investigated how direct health care cost per patient varies with clinical stage.
Objective: The aim of this study was to determine the stage-specific direct health care costs for CMM patients compared to the health care costs in the general population in the County of Östergötland, Sweden.
Methods: Cutaneous malignant melanoma patients in the County of Östergötland diagnosed 2005-2012 were identified from the Swedish cancer registry. Information on clinical stage was collected from the Swedish Melanoma Register (SMR) and cost data from the Cost per Patient database (CPP) for 1075 CMM patients in Östergötland. CPP contains costs associated with all health care contacts per patient including inpatient, outpatient and primary care. The CMM-related costs were defined as the difference in mean health care costs between CMM patients and general population.
Results: The first year after CMM diagnosis, the average health care costs for CMM patients were 2.8 times higher than in the general population. The health care cost ratio varied from 2.0 (stage I) to 10.1 (stage IV) and the CMM-related costs per patient-year varied from €2 670 (stage I) to €29 291 (stage IV). The mean health care costs decreased over time but remained significantly higher than in the general population for all clinical stages. During the first year after diagnosis, patients in clinical stage III-IV (7% of CMM patients) accounted for 27% of the total CMM-related health care costs.
Conclusions: The direct health care costs for CMM patients were significantly higher than in the general population independent of clinical stage. CMM patients diagnosed in clinical stage III-IV were associated with particularly high costs and the health care system may save resources by finding CMM patients in earlier stages.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jdv.13110 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advancing PrEP for HIV prevention: innovations and the imperative to preserve comprehensive care.
BMC Glob Public Health
January 2025
Edson College of Nursing and Health Innovation, Arizona State University, Downtown Phoenix Campus, Phoenix, AZ, USA.
Investigation of the total anticholinergic load of reported anticholinergic drug-related adverse events using the Japanese adverse drug event report database: a retrospective pharmacovigilance study.
J Pharm Health Care Sci
January 2025
Department of Medical Molecular Informatics, Meiji Pharmaceutical University, Kiyose, 204-8588, Japan.
Background: The Anticholinergic Risk Scale and Total Anticholinergic Load were developed to assess the risks associated with anticholinergic drugs. Recently, the Japan Anticholinergic Risk Scale was introduced; however, the total anticholinergic load for adverse events has not been clarified, and the criteria for risk assessment in clinical practice have not been established. In this study, we used data from the Japanese Adverse Drug Event Report (JADER) database provided by the Pharmaceuticals and Medical Devices Agency to determine the total anticholinergic load associated with reported adverse events related to anticholinergic syndrome.
View Article and Find Full Text PDFProfessionals' perception on nutritional care of adult patients in comprehensive specialized hospitals of East Wollega Zone, Ethiopia.
BMC Nutr
January 2025
Department of Public Health , Institute of Health Sciences, Wollega University, Nekemte Town, Post Box 395, Nekemte, Oromia, Ethiopia.
Background: Adult patients suffering from malnutrition in hospitals are often overlooked, especially in low-income countries. Health care professionals play a vital role in identifying and managing the nutritional needs of patients. However, their perception regarding the nutritional care of adult patients have not been thoroughly examined.
View Article and Find Full Text PDFBiofilm characterisation of Mycoplasma bovis co-cultured with Trueperella pyogenes.
Vet Res
January 2025
Animal Health Unit, Department of Veterinary Science, School of Veterinary Medicine, Rakuno Gakuen University, Ebetsu, Hokkaido, Japan.
Mycoplasma pneumonia, caused by Mycoplasma bovis (Mycoplasmopsis bovis; M. bovis), is linked with severe inflammatory reactions in the lungs and can be challenging to treat with antibiotics. Biofilms play a significant role in bacterial persistence and contribute to the development of chronic lesions.
View Article and Find Full Text PDFA qualitative process evaluation of SBIRT implementation in pediatric trauma centers using the Science to Service Laboratory implementation strategy.
Implement Sci Commun
January 2025
Center for Dissemination and Implementation Science, Northwestern University Feinberg School of Medicine, 633 N St Clair Street, Chicago, IL, USA.
Background: Screening, Brief Intervention, and Referral to Treatment (SBIRT) is an evidence-based practice that can identify adolescents who use alcohol and other drugs and support proper referral to treatment. Despite an American College of Surgeons mandate to deliver SBIRT in pediatric trauma care, trauma centers throughout the United States have faced numerous patient, provider, and organizational level barriers to SBIRT implementation. The Implementing Alcohol Misuse Screening, Brief Intervention, and Referral to Treatment Study (IAMSBIRT) aimed to implement SBIRT across 10 pediatric trauma centers using the Science-to-Service Laboratory (SSL), an empirically supported implementation strategy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!